Rebinyn, a recombinant DNA-derived coagulation Factor IX concentrate, temporarily replaces the missing coagulation Factor IX in hemophilia B patients. Novo Nordisk announced that the Food and Drug ...
Hemophilia B, also called factor IX (FIX) deficiency, is an inherited condition that prevents blood from clotting normally. This means that if you experience a cut, scrape, or injury, the bleeding ...
MISSISSAUGA, ON, April 11, 2018 /CNW/ - Today, in Canada, Novo Nordisk announced the launch and availability of Rebinyn ® (Coagulation Factor IX (Recombinant), pegylated), an anti-hemophilic factor ...
PLAINSBORO, N.J., May 21, 2018 /PRNewswire/ -- A new head-to-head pharmacokinetic study showed that adults with hemophilia B who received a single dose (50 IU/kg) of Rebinyn ® [Coagulation Factor IX ...
Rebinyn, a recombinant DNA-derived coagulation Factor IX concentrate with an extended half-life, was approved by the Food and Drug Administration (FDA) in May 2017. Novo Nordisk announced the launch ...
Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for Rebinyn for the treatment of adults and children with haemophilia B. Rebinyn is ...
Bagsværd, Denmark, 31 May 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for REBINYN ® for the treatment of adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results